Neuropace (NPCE) Stock Price
Neuropace Price
Revenue has compounded at 22.4% per year over the past 6 years to 92.53 M USD. Neuropace's net margin stands at -23.2%, up from -95.5% several years earlier. Analysts set a median price target of 21.00 USD, implying 44.4% above the current price. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus. The stock trades about 55% above its 52-week low.
Neuropace stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Neuropace over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Neuropace stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Neuropace's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Neuropace Price |
|---|---|
| 9/21/2026 | 14.54 USD |
| 9/18/2026 | 14.45 USD |
| 9/17/2026 | 14.15 USD |
| 9/16/2026 | 14.32 USD |
| 9/15/2026 | 14.18 USD |
| 9/14/2026 | 14.59 USD |
| 9/13/2026 | 14.18 USD |
| 9/11/2026 | 13.94 USD |
| 9/10/2026 | 13.87 USD |
| 9/9/2026 | 14.50 USD |
| 9/8/2026 | 14.82 USD |
| 9/4/2026 | 14.90 USD |
| 9/3/2026 | 14.75 USD |
| 9/2/2026 | 15.19 USD |
| 9/1/2026 | 14.74 USD |
| 8/31/2026 | 14.65 USD |
| 8/30/2026 | 14.43 USD |
| 8/28/2026 | 14.35 USD |
| 8/27/2026 | 14.63 USD |
| 8/26/2026 | 14.68 USD |
| 8/25/2026 | 14.16 USD |
| 8/24/2026 | 14.15 USD |
| 8/21/2026 | 14.03 USD |
| 8/20/2026 | 14.02 USD |
| 8/19/2026 | 14.94 USD |
| 8/18/2026 | 14.39 USD |
| 8/14/2026 | 14.77 USD |
| 8/13/2026 | 14.51 USD |
| 8/12/2026 | 14.84 USD |
| 8/10/2026 | 14.88 USD |
Neuropace Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Neuropace Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.00 | 41.00 | 45.00 | 45.00 | 65.00 | 79.00 | 99.00 | 100.00 | 122.00 | 151.00 | 188.00 | 224.00 |
| – | 13.89 | 9.76 | – | 44.44 | 21.54 | 25.32 | 1.01 | 22.00 | 23.77 | 24.50 | 19.15 |
| 72.22 | 73.17 | 73.33 | 71.11 | 73.85 | 74.68 | 77.78 | 77.78 | 77.78 | 77.78 | 77.78 | 77.78 |
| 26.00 | 30.00 | 33.00 | 32.00 | 48.00 | 59.00 | 77.00 | 77.78 | 94.89 | 117.44 | 146.22 | 174.22 |
| -20.00 | -12.00 | -28.00 | -41.00 | -27.00 | -21.00 | -16.00 | -10.00 | -2.00 | 9.00 | 3.00 | 12.00 |
| -55.56 | -29.27 | -62.22 | -91.11 | -41.54 | -26.58 | -16.16 | -10.00 | -1.64 | 5.96 | 1.60 | 5.36 |
| -29.00 | -24.00 | -36.00 | -47.00 | -32.00 | -27.00 | -21.00 | -18.00 | -10.00 | -5.00 | -4.00 | 3.00 |
| – | -17.24 | 50.00 | 30.56 | -31.91 | -15.63 | -22.22 | -14.29 | -44.44 | -50.00 | -20.00 | -175.00 |
| 11.10 | 11.10 | 17.00 | 25.00 | 26.00 | 29.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Neuropace generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Neuropace retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Neuropace's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Neuropace has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Neuropace's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Neuropace stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Neuropace Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Neuropace business model & stock analysis
Neuropace SWOT Analysis
Strengths
Neuropace Inc has several strengths that contribute to its success in the market. These strengths include:
- A strong and experienced management team that has a deep understanding of neurology and medical device industry.
- Patented technology that provides a unique and effective solution for the treatment of neurological disorders.
- A strong product portfolio with innovative devices that have been clinically proven to provide positive patient outcomes.
- An established customer base and distribution network that helps in market penetration and expansion.
Weaknesses
Despite its strengths, Neuropace Inc also has a few weaknesses that it needs to address in order to maintain its competitive position:
- Relatively high product costs compared to some competitors, making it less accessible to certain customer segments.
- Dependency on regulatory approvals for new products, which can result in delays in product launches.
- Limited global presence, primarily focused on a few key markets, which restricts the company's potential for growth.
Opportunities
Neuropace Inc can capitalize on several opportunities in the market to further expand its business:
- Increasing demand for innovative medical devices in the field of neurology, driven by a rise in neurological disorders.
- Expanding into untapped international markets to reach a wider customer base and increase revenue.
- Collaboration and partnerships with healthcare organizations and research institutions to drive product development and market penetration.
- Continued advancements in technology that can lead to the development of more efficient and cost-effective devices.
Threats
Neuropace Inc faces certain threats that could impact its growth and market position negatively:
- Intense competition from other medical device companies offering similar neurostimulation solutions.
- Changes in healthcare regulations and reimbursement policies that could affect the pricing and accessibility of Neuropace's products.
- Rapidly evolving technology landscape, which could render the company's existing devices obsolete if not consistently updated.
- Possible economic downturns or financial instability affecting healthcare spending and customer purchasing power.
Neuropace Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Neuropace Segments
Neuropace Revenue by Region
Max
Details
Neuropace Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Neuropace historical P/E ratio, EBIT multiple, and P/S ratio
Neuropace annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Neuropace's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Neuropace's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Neuropace's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Neuropace shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Neuropace forecasts and price targets in September 2026
Analyst Price Targets 2026Neuropace Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 7/29/2026 | Maintained | Buy | – | |
| 5/15/2026 | Maintained | Buy | – | |
| 1/27/2026 | Maintained | Buy | – | |
| 12/16/2025 | Maintained | Buy | 49 | |
| 12/10/2025 | Maintained | Overweight | 53 | |
| 11/5/2025 | Maintained | Overweight | 58 | |
| 11/5/2025 | Maintained | Overweight | 53 | |
| 8/13/2025 | Maintained | Overweight | 58 | |
| 5/14/2025 | Maintained | Overweight | 53 | |
| 5/14/2025 | Maintained | Overweight | 38 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Neuropace Earnings Calls
Neuropace Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/3/2026 | -0.11USD | - | 27.14 MUSD | - | 2026 Q3 |
| 8/11/2026 | -0.22USD | -0.18USD | 22.61 MUSD | - | 2026 Q2 |
| 5/12/2026 | -0.19USD | -0.20USD | 21.65 MUSD | - | 2026 Q1 |
| 3/3/2026 | -0.14USD | -0.08USD | 24.75 MUSD | - | 2025 Q4 |
| 11/4/2025 | -0.20USD | -0.11USD | 25.03 MUSD | - | 2025 Q3 |
| 8/12/2025 | -0.24USD | -0.26USD | 24.43 MUSD | - | 2025 Q2 |
| 3/4/2025 | -0.25USD | -0.18USD | 21.56 MUSD | - | 2024 Q4 |
| 11/12/2024 | -0.26USD | -0.19USD | 20.91 MUSD | - | 2024 Q3 |
| 8/13/2024 | -0.29USD | -0.26USD | 18.30 MUSD | - | 2024 Q2 |
| 5/8/2024 | -0.32USD | -0.32USD | 17.30 MUSD | - | 2024 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Neuropace stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Neuropace shareholder structure
| % | Name |
|---|---|
9.97008% | |
8.80025% | |
8.64924% | |
8.02416% | |
7.48973% | |
4.54995% |
Neuropace Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
16.80% | SEC ↗ | |
16.20% | SEC ↗ | |
16.20% | SEC ↗ | |
16.20% | SEC ↗ | |
9.13% | SEC ↗ | |
8.40% | SEC ↗ | |
8.30% | SEC ↗ | |
7.60% | SEC ↗ | |
6.20% | SEC ↗ | |
5.82% | SEC ↗ |
Neuropace Executives and Management Board
10 members · avg. age 60 · 40 % women
Mr. Joel Becker (57)
President, Chief Executive Officer, Director · since 2023
3.02 M USD
Management
Dr. Martha Morrell (69)
Chief Medical Officer
Mr. Patrick Williams (52)
Chief Financial Officer
Board of Directors
Mr. Frank Fischer (83)
Independent Chairman of the Board · since 1997
Ms. Lisa Andrade (53)
Independent Director
Ms. Rakhi Kumar (45)
Independent Director
Ms. Renee Ryan (55)
Independent Director
Dr. Uri Geiger (57)
Independent Director
Mr. Joseph Lacob (68)
Independent Director
Neuropace Supply Chain
Neuropace Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.28 | 0.91 | — |
Frequently asked questions about Neuropace
The business model of Neuropace Inc involves developing and commercializing medical devices to treat neurological disorders. Specializing in responsive neurostimulation, the company's flagship product is the RNS® System. This implantable device, approved by the FDA, is designed to detect abnormal electrical brain activity and deliver therapeutic electrical pulses to the affected area, aiming to reduce seizures in patients with epilepsy. By providing innovative technology and comprehensive support, Neuropace Inc aims to improve the quality of life for individuals suffering from refractory epilepsy.
Neuropace Inc is primarily active in the medical device industry.
The main competitors of Neuropace Inc in the market include Medtronic, Cyberonics, and Boston Scientific.
NeuroPace Inc is a leading medical technology company focused on providing innovative solutions for the treatment of neurological disorders. Founded in 1997, the company has been dedicated to developing responsive neurostimulation systems. Their flagship product, RNS System, is the world's first and only FDA-approved brain-responsive neurostimulator for the treatment of epilepsy. With a commitment to improving the quality of life for patients with uncontrolled seizures, NeuroPace Inc continues to advance the field of neuromodulation. Their groundbreaking technology offers hope and relief to individuals who have not responded well to traditional epilepsy treatments.
Neuropace Inc has achieved several significant milestones. The company successfully developed and received FDA approval for the RNS System, a novel medical device for treating epilepsy. This innovative device has revolutionized the treatment landscape for patients with drug-resistant focal epilepsy. Neuropace Inc has also made remarkable strides in research and development, continually enhancing their technology and expanding its applications. Furthermore, the company has established collaborations with renowned medical centers worldwide, further validating the efficacy and safety of their products. With these notable achievements, Neuropace Inc has solidified its position as a leader in the field of neurostimulation therapies for patients suffering from epilepsy.
Neuropace Inc is primarily present in the United States.
Neuropace Inc represents values of innovation, patient-centered care, and commitment to improving the lives of individuals with neurological disorders. The company focuses on developing innovative medical technologies to address unmet medical needs in the field of epilepsy management. With a corporate philosophy centered on offering personalized and advanced treatment options, Neuropace Inc aims to empower patients and healthcare professionals in their battle against epilepsy. By leveraging cutting-edge neurostimulation technology and continuous monitoring, the company strives to provide effective solutions for better seizure control and enhanced quality of life for epilepsy patients.
Analysts currently set an average price target of 21.00 USD for the Neuropace stock (median: 21.00 USD), implying +45.3 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Neuropace stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Neuropace to generate revenue of 100.33 M USD and earnings per share of -0.57 USD.
Converted at the current exchange rate, the Neuropace share trades at 12.68 EUR (14.54 USD).
The Neuropace share (NPCE) is listed on 1 stock exchanges, including: NASDAQ (NPCE).
The company Neuropace Inc. specializes in manufacturing and distributing medical devices. It was founded in 1997 and is based in Mountain View, California. Its main focus is on developing implantable medical devices for the treatment of epilepsy. Neuropace Inc.'s main expertise is in the production of neurostimulators. These devices are implanted directly in the brain and deliver targeted impulses that can reduce or even prevent epilepsy seizures. The technology used in these neurostimulators was developed and patented by Neuropace itself. Neuropace's neurostimulators are capable of detecting seizures in patients and then initiating targeted brain stimulation to interrupt the seizure. The devices can therefore be considered a kind of "emergency shutdown" for the brain. In addition, the devices can also be used for seizure prevention by continuously emitting signals to keep the brain calm. In addition to developing and manufacturing neurostimulators, Neuropace also offers clinical services. The company is actively involved in conducting clinical trials to investigate the safety and efficacy of neurostimulators. It also provides training for medical professionals to properly implant the device and care for patients. Neuropace's business model is based on the manufacture and sale of neurostimulators and the provision of clinical services. The company operates a direct sales model and sells its products directly to medical professionals and hospitals. The company also engages in active research and development to continuously improve the effectiveness of its products and bring new products to the market. The company operates globally. Its products are approved and focused in the US, Canada, and Europe, with plans to obtain further approvals in other parts of the world due to high demand. It is expected that the company is planning extensive expansions. Overall, Neuropace is an innovative company specializing in the development of novel medical devices that can help improve the quality of life for people with epilepsy. With its unique technology and emphasis on ensuring the highest possible safety and efficacy of its devices, Neuropace has achieved a leading position in the market and plans to continue growing in the future.
The expected revenue of Neuropace is 100.33 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Neuropace is -18.84 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Neuropace is currently -25.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neuropace stock.
The price-to-sales ratio (P/S) of Neuropace is currently 4.78. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Neuropace stock.
The Eulerpool Quality Score for Neuropace is 3/10.
The ISIN of Neuropace is US6412881053. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Neuropace is NPCE. The ticker symbol is used to trade Neuropace shares on the stock exchange.
Neuropace paid dividends every year for the past 0 years.
Neuropace is assigned to the 'Health' sector.
The dividends of Neuropace are distributed in USD.
Neuropace stock
Neuropace Peer Group
Neuropace Ticker
Neuropace FIGI
All fundamentals and in-depth analysis of Neuropace
Our stock analysis for Neuropace stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuropace. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.